12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SGN-CD19A: Phase I started

Seattle Genetics began an open-label, dose-escalation, U.S. Phase I trial to evaluate SGN-CD19A given every 3 weeks in about 25 patients with relapsed or refractory...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >